At the end of every heartbeat, cardiac myocytes must relax to allow filling of the heart. Impaired relaxation is a significant factor in heart failure, but all pathways regulating the cardiac relaxation apparatus are not known. Haploinsufficiency of the T-box transcription factor Tbx5 in mouse and man causes congenital heart defects (CHDs) as part of Holt-Oram syndrome (HOS). Here, we show that haploinsufficiency of Tbx5 in mouse results in cellautonomous defects in ventricular relaxation. Tbx5 dosage modulates expression of the sarco(endo)plasmic reticulum Ca 2؉ -ATPase isoform 2a encoded by Atp2a2 and Tbx5 haploinsufficiency in ventricular myocytes results in impaired Ca 2؉ uptake dynamics and Ca 2؉ transient prolongation. We also demonstrate that Tbx5 can activate the Atp2a2 promoter. Furthermore, we find that patients with HOS have significant diastolic filling abnormalities. These results reveal a direct genetic pathway that regulates cardiac diastolic function, implying that patients with structural CHDs may have clinically important underlying anomalies in heart function that merit treatment.
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calcium ͉ cardiac ͉ transcription ͉ ventricular ͉ SERCA2a T he mammalian heart must beat several thousand times per hour throughout an entire lifetime to circulate blood. An important component of each cardiac cycle is the relaxation of the heart to allow complete filling of the chambers in preparation for the next expulsion of blood. Cardiac relaxation in the ventricles has two components: an active component, during which the muscle actively relaxes after each contraction, followed by a passive component, in which the ventricular chambers distend in response to the influx of blood from the atria. The active component involves highly regulated Ca 2ϩ removal from the cytosol to allow dissociation between actin and myosin filaments (1, 2) . The major effectors of cardiac relaxation are the sarco(endo)plasmic reticulum Ca 2ϩ ATPase isoform 2a (SERCA2a), plasma membrane Ca 2ϩ ATPases (PMCAs), and Na ϩ /Ca 2ϩ exchangers (NCXs) (1, 2) . Impaired relaxation, or diastolic dysfunction, is an important component of heart failure. Indeed, a significant portion of heart failure patients have normal systolic function, but significantly altered diastolic function (1) . Although the roles and importance of the cardiac relaxation machinery have been studied extensively (1) (2) (3) , and although it is clear that there are alterations in the expression of SERCA2a or NCX1 in cardiomyopathies (1, 4) , the regulation of expression of these molecules at the genetic level is not fully understood.
Several transcription factors have been identified as key regulators of cardiac morphogenesis (5, 6) , and their importance has been highlighted by the identification of mutations that are causal of inherited congenital heart defects (CHDs) in genes encoding these factors (5, 6) . However, defined roles for cardiac transcription factors in regulating pathways critical for normal heart function have been largely elusive, with a few exceptions (7) (8) (9) (10) (11) .
The T-box transcription factor, Tbx5, is a key regulator of cardiac morphogenesis and gene expression. It is mutated in humans with Holt-Oram syndrome (HOS), a dominant inherited disease characterized by upper limb defects and CHDs (12) . The CHDs found in HOS usually arise from atrial or ventricular septation defects or from atrioventricular node conduction system defects. A mouse model of HOS, in which one allele of Tbx5 was deleted (Tbx5 del/ϩ mice), has provided some insight into the etiology of the CHDs caused by Tbx5 haploinsufficiency (7, 13) . We observed significant diastolic dysfunction in Tbx5 del/ϩ mice (14) , suggesting that Tbx5 may be important for regulating components of the cardiac relaxation machinery. However, such relaxation defects might be secondary to volume load alterations because of large atrial septal defects (ASDs) in these mice.
In the present study, we show that Tbx5 regulates ventricular myocyte relaxation in a cell-autonomous manner by direct modulation of the expression of SERCA2a. Patients with HOS also have diastolic defects that resemble restrictive cardiomyopathy. This defines a Tbx5-dependent pathway for the transcriptional control of diastolic function, with potential implications for the pathogenesis of heart failure and the management of altered heart function in patients with CHDs.
Results

Tbx5 Dosage and Cell-Autonomous Diastolic Dysfunction. Tbx5
del/ϩ mice have impaired relaxation as defined by decreased E/A wave ratio and prolonged isovolumic relaxation time (IVRT) measured by Doppler ultrasound (Fig. 1) (14) . At the beginning of diastole, early rapid filling of the ventricle results in the E wave, and subsequent atrial contraction results in the A wave. With diastolic abnormalities, both the size and shape of these respective waveforms can change: Early diastolic dysfunction will often result in a prolonged E wave (increased deceleration time) and a decrease in the E/A wave ratio. With progressive diastolic disease and increasing left atrial pressure, this pattern may be reversed (i.e., increasing severity of disease will decrease the E/A ratio). IVRT is prolonged in the early stages of diastolic dysfunction; the myocardium takes longer to relax because of abnormal calcium cycling. In more severe disease states, IVRT is paradoxically shortened as a result of left atrial hypertension. Smaller left ventricle (LV) end-diastolic diameter (EDD) and end-systolic diameter (ESD) in Tbx5 del/ϩ mice also support the finding of impaired diastolic function (14) .
Because Tbx5 del/ϩ mice have ASDs that alter intracardiac volumes significantly (7, 14) , we used a tissue-specific deletion strategy to create haploinsufficiency of Tbx5 in ventricular myocytes only. Mice bearing loxP-flanked Tbx5 sequences (Tbx5 ldn/ldn mice) (13) Vdel/ϩ mice also have reduced E/A ratios, albeit less severe than in Tbx5 del/ϩ mice, and prolonged IVRT ( Fig. 1 and Table 2 ). M-mode echocardiography also showed reduced LV EDD and ESD (Table 2 ). Masson's trichrome staining revealed no fibrosis in either Tbx5
Vdel/ϩ or Tbx5 del/ϩ mice ( Fig. 1) . Thus, ventricle-restricted haploinsufficiency of Tbx5 results in diastolic dysfunction.
Tbx5 Modulates SERCA2a Expression. Because Tbx5 haploinsufficiency results in a cell-autonomous defect in myocyte relaxation, we examined components of the cardiac relaxation machinery.
We found a significant decrease in LV protein levels of SERCA2a in Tbx5 Vdel/ϩ and Tbx5 del/ϩ mice, whereas phospholamban (PLN), Na ϩ /Ca 2ϩ exchanger 1 (NCX1), and ryanodine receptor 2 (RyR2) levels were unaltered ( Fig. 2A) . We observed parallel decreases in mRNA levels of Tbx5 and Atp2a2, which encodes SERCA2a, in LV RNA from Tbx5 Vdel/ϩ and Tbx5 del/ϩ mice ( Fig. 2B ). SERCA2a functions to pump Ca 2ϩ into the SR. Thus, as a functional measure of SERCA2a activity, we measured Ca 2ϩ uptake from LV tissue. The rate and amplitude of Ca 2ϩ uptake were decreased similarly in Tbx5
Vdel/ϩ and Tbx5 del/ϩ mice ( Fig. 2C and Table 3 ). We also measured Ca 2ϩ transients in isolated LV myocytes, detecting a normal amplitude, but a decreased rate of decay of the Ca 2ϩ transients in myocytes from Tbx5 del/ϩ and Tbx5
Vdel/ϩ mice ( Fig. 2D and data not shown). Overall, these results are consistent with impaired SR Ca 2ϩ cycling in LV cardiac myocytes because of decreased SERCA2 levels in Tbx5 Vdel/ϩ and Tbx5 del/ϩ mice. If the defects in diastolic function are truly specific to altered SERCA2a, they should be reversible upon deletion of PLN, a negative regulator of SERCA2a function (2), which would lead to a specific increase in the affinity of SERCA2a for Ca 2ϩ . Indeed, Tbx5 Vdel/ϩ ;PLN Ϫ/Ϫ mice had normal diastolic function ( Fig. 1 and Table 1 ) and increased rates of Ca 2ϩ uptake that were intermediate between wild-type mice and those seen in PLN Ϫ/Ϫ hearts ( Fig. 2C and Table 3 ). Interestingly, we also observed increased SERCA2a protein levels in Tbx5 vdel/ϩ; PLN Ϫ/Ϫ hearts, suggesting that a feedback mechanism involving Ca 2ϩ also might regulate SERCA2a transcription. It is not clear how this feedback mechanism might function, but recent data have demonstrated that intracellular signaling pathways, including Ca 2ϩ , can potentiate the activity of certain transcription factors (16) (17) (18) , and Ca 2ϩ channels themselves can act as transcription factors in a Ca 2ϩ -dependent manner (19) . Thus, the transcriptional regulation of Atp2a2 by Tbx5 may not reach its full potential under the conditions of abnormal Ca 2ϩ regulation imposed by suboptimal levels of SERCA2a. When Ca 2ϩ regulation is restored in Tbx5 vdel/ϩ; PLN Ϫ/Ϫ hearts by a sharpening of the curve of Ca 2ϩ decay, the full potential of Tbx5 as a transcription factor may then be realized. Alternatively, altered Ca 2ϩ kinetics might affect pathways parallel to Tbx5 that also are important for the regulation of SERCA2a expression. Regardless of this potential additional mechanism, the fact that SERCA2a protein and mRNA are decreased specifically in parallel with Tbx5 dosage, and that this is rescued by ablation of PLN, supports the view that the defects in diastolic function caused by a decreased dosage of Tbx5 are due to a specific effect on SR Ca 2ϩ cycling via the down-regulation of SERCA2a levels, leading to a decrease in total SERCA2a activity. We isolated genomic sequences upstream of mouse Atp2a2, including 4 kb of upstream sequences and the endogenous promoter, and fused them to the luciferase reporter gene. Cotransfection of the Atp2a2-luciferase reporter constructs with a Tbx5 expression construct showed that sequences up to 4 kb upstream of the Atp2a2 transcriptional start site conferred activation of the reporter gene in response to exogenously added Tbx5 (Fig. 2E) . Thus, Atp2a2 is likely to be a direct, dosagesensitive target of Tbx5 in cardiac myocytes.
Diastolic Defects in HOS Patients. Our findings suggest that haploinsufficiency of TBX5 in humans also should result in diastolic filling abnormalities. We analyzed a cohort of HOS patients and age-matched controls by Doppler ultrasound. Of 13 patients suitable for enrollment in the study, 8 participated. HOS was diagnosed clinically in all patients (Table 4) . One had a TBX5 mutation, whereas the others did not have genetic testing. Both pulsed Doppler of the mitral inflow and LV tissue Doppler showed significant differences between the HOS patients and the control group (Fig. 3 and Table 5 ). In patients with HOS, the early diastolic flow (E wave) was increased (P ϭ 0.003), the late diastolic flow (A wave) was decreased (P ϭ 0.026), with the early/late ratio increased (P ϭ 0.001). Although IVRT was prolonged in some patients, the trend did not achieve overall statistical significance (P ϭ 0.13). Tissue Doppler velocities were decreased in all areas, but were most notable in the interven- tricular septum (IVS) (P ϭ 0.005). The E/EЈ ratio was increased for the mitral valve (MV) (P ϭ 0.03) and more markedly at the IVS (P ϭ 0.0001), indicating a restrictive pattern of filling. The severity and type of diastolic filling abnormalities was quite variable in our human subjects. To illustrate individual cases, we compared echocardiogram data to published normal values (Table 6 ) (20) . Patient 1 was 12 years old and had small intracardiac lesions that closed spontaneously. The pattern of diastolic filling abnormalities seen was similar to that of the mouse model; deceleration time was prolonged (197 ms; Ͼ2 SD from mean), but IVRT was within normal limits (Table 6 ). Tissue Doppler measurements were marginally low. More notably, however, both of the corresponding E/EЈ ratios showed a marked increase. There also was the prominent reversal of flow in the pulmonary veins during atrial systole, another marker of diastolic filling abnormality. This pattern suggests early relaxation abnormalities (prolonged deceleration time), which may be progressing to a more restrictive pattern of diastolic filling (elevated E/EЈ ratio). Patient 4 had a structurally normal heart, yet his echocardiogram findings are consistent with a restrictive cardiomyopathy.
Discussion
In the present work, we showed that Tbx5 regulates cardiac myocyte relaxation properties by direct regulation of SERCA2 protein levels. This establishes a pathway in the regulation of cardiac diastolic function, with potential implications for the management of CHD patients.
Our identification of Tbx5 as a dosage-sensitive regulator of Atp2a2 gene expression provides a key entry point in uncovering pathways that modulate cardiac relaxation and SR Ca 2ϩ cycling from a transcriptional perspective. To date, the transcriptional pathways that regulate the molecular components of the cardiac myocyte relaxation machinery have remained elusive. There have been suggestions that Sp1 or related factors are involved in the decreased expression of Atp2a2 in cardiac hypertrophy (21) and that ATF6 increases Atp2a2 mRNA under stress conditions (22) . However, no endogenous transcription factor has been shown to be critical for in vivo regulation of Atp2a2 or other components of the cardiac myocyte relaxation machinery.
Significantly, our results suggest that the function of Tbx5 is not necessarily restricted to the embryo. The importance of the persistent expression of key developmental transcription factors into adulthood is becoming clearer. Recently, the requirement for Nkx2-5 in postnatal cardiac growth and function has been demonstrated (9) . Mice with a ventricular myocyte-restricted deletion of Nkx2-5 have a range of defects that includes conduction system disease and cardiomyopathy. Similarly, mice with ablation of the Homeodomain-only protein (Hop) gene have postnatal ECG anomalies that reflect the predominant postnatal expression of Hop in the conduction system (11) . Finally, postnatal deletion of the zinc-finger transcription factor, Gata4, has shown that it plays a role in regulating contractile and diastolic function, and it also is required for adaptative hypertrophy after pressure overload (23, 24) . In these cases, functional deficiencies were accompanied by increased fibrosis and apoptosis, suggesting that they were secondary events. In the case of Tbx5, our results uncovered a cell-autonomous, dosage-specific postnatal role, which is distinct from the complete loss of function that the above-mentioned studies have described. Thus, Tbx5 may have a specific and prominent role in regulating the postnatal diastolic function of the heart. Our results show that HOS in humans also is associated with altered diastolic function. The prolonged isovolumic relaxation time is compatible with early diastolic impaired relaxation, similar to Tbx5 haploinsufficient mice, although the difference failed to reach overall significance. The remaining indices suggest abnormal chamber compliance and myocardial stiffness. Most notably, the E/EЈ (the best available index of myocardial stiffness) (25) was elevated in our patients. Overall, some discordance was seen between the diastolic phenotype observed in our mouse model and humans. This result is to be expected given the progressive nature of diastolic dysfunction in clinical syndromes and differences in physiological adaptation in mice and humans. Furthermore, the temporal progression from abnormal relaxation to pseudonormalization to an overtly restrictive late diastolic pattern of dysfunction is well described in many disease states (26) . Although there is some evidence of a persisting relaxation abnormality, our data suggest that, in the long term, diastolic disease in HOS may evolve to a predominantly late-diastolic abnormality consistent with increased LV myocardial stiffness. Nevertheless, our patients were clinically asymptomatic, which is not surprising given the magnitude of the diastolic filling abnormalities in this relatively young population. Individuals (Table 6 ) fulfilled accepted criteria for diastolic filling abnormalities, highlighting the variable expressivity of TBX5 mutations in human disease.
The identification of a Tbx5-dependent pathway in the regulation of postnatal diastolic function has several clinical implications. First, it provides an entry point to understand the regulation of the molecular components critical for normal diastolic function. Second, diastolic dysfunction in Tbx5 haploinsufficient mice occurs without any other defect in heart structure or function. Therefore, our understanding of a specific component of heart failure will be greatly enhanced by elucidating the role of Tbx5 in this specific component of heart failure. Third, our finding may have direct implications for the management of patients with corrected CHDs. Congenital defects are well known to have severe sequelae, and patients may progress to heart failure in adulthood even after successful childhood closure of a septal defect (27) (28) (29) . Our results suggest that this may be caused, in part, by impaired diastolic function from abnormal regulation of SERCA2 or other components that regulate myocyte relaxation. In support of this notion, ultrasound measurement of heart chamber volumes in utero has shown a significantly reduced EDD in fetuses with CHDs, compared with normal controls (30) . Furthermore, a recent study has shown that patients with ASDs do not recover normal diastolic function after ASD closure, indicating the possibility of an underlying primary defect (31) . Moreover, in patients with Marfan syndrome, primary LV dysfunction has been reported, suggesting that underlying, clinically significant defects in heart function, unrelated to structural anomalies, may be widespread (32) . Finally, ventricular deletion of Nkx2-5 in the mouse uncovered a pathway for cardiac growth that implied continued requirement for Nkx2-5 in ventricular myocytes. This finding was extended to patients with NKX2-5 mutations, which in some cases led to heart failure (9).
Because we have found defects in diastolic function in humans with HOS that are similar to those in the mice, it is very likely that we have uncovered a pathway that has direct relevance to CHD patients. An ascertainment of the global relevance of the current findings to a clinical setting will require evaluation of a large cohort of patients with congenital heart defects of defined and varied genetic etiology.
Materials and Methods
Mouse Lines and Characterization. Tbx5 ldn/ldn , Nkx2.5Cre mice, and PLN ϩ/Ϫ were generated as described (13, 15, 33) . MRI, ultrasound, and histology were performed as described (13, 14) .
Antibodies and Immunoblots. mAb 1D11 was kindly provided by R. Johnson (Merck Laboratories, West Point, PA). mAB IID8F6 against SERCA2 was a gift from K. Campbell (University of Iowa, Iowa City, IA). mAb NXC1 (SWANT) and mAb ryanodine receptor 2 (Affinity Bioreagents) were obtained commercially. Mouse ventricles were isolated, washed in PBS, and homogenized in 250 mM sucrose, 50 mM Tris⅐HCl (pH 7.4), 1 mM PMSF, and 20 g/ml aprotinin. Lysates were isolated after a 15-min centrifugation at 8,000 ϫ g, and the supernatant was collected and used. Immunoblots were performed as described (34) . Membrane signals were quantified by using a BioRad Fluor-S Multiimager documentation system. Ca 2؉ Transport. ATP and oxalate-dependent Ca 2ϩ uptake activities in wholeheart homogenates were measured by using a Millipore filtration method (35, E wave, early mitral inflow; A wave, late mitral inflow; IVRT, isovolumic relaxation time; MV-EЈ and MV-AЈ, mitral annulus early (EЈ) and late (AЈ) myocardial velocities; IVS-EЈ and IVS-AЈ, interventricular septum early (EЈ) and late (AЈ) myocardial velocities; E/EЈ ratio, inflow velocity divided by the tissue Doppler velocity; A-wave reversal, peak velocity of retrograde blood flow in the pulmonary vein during atrial systole. * , P Ͻ 0.05 vs. healthy patient data.
